Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
713 Leser
Artikel bewerten:
(2)

Cloud DX Inc.: Cloud DX to Present on Teladoc Partnership and More at Emerging Growth Conference

Finanznachrichten News

Individual and institutional investors, advisors, and analysts are invited to attend Cloud DX's interactive presentation at the Emerging Growth Conference

  • Cloud DX and Teladoc Health announced a new partnership to deliver integrated remote patient monitoring (RPM) solutions to providers across Canada
  • CEO Robert Kaul will present on the implications of the Agreement and update investors on other Cloud DX initiatives including the partnership with Medtronic

KITCHENER, ON / ACCESSWIRE / August 30, 2022 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), is pleased to announce that it has been invited to present at the Emerging Growth Conference on August 31, 2022.

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the company's Founder & CEO, Robert Kaul.

Cloud DX is emerging as the partner of choice among the largest global medical technology companies to provide innovative, best-in-class remote patient monitoring (RPM) solutions. On August 26, the company jointly announced a partnership with the world's largest telemedicine company, Teladoc Health, integrating Teladoc's virtual care solution Solo with the award-winning Cloud DX Connected Health platform.

The company also has an exclusive relationship with Medtronic (NYSE: MDT), the world's largest MedTech company as the RPM solution for healthcare pathways across Canada, including post-surgical care in the home, reducing complications from surgery.

Mr. Kaul will present on recent news and may subsequently open the floor for questions. Please ask your questions during the event and we will do our best to get through as many of them as possible. The Cloud DX presentation will start at 10:30 AM Eastern time and run for 30 minutes.

Please register here to ensure you are able to attend the Conference and receive any updates that are released.

If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available on EmergingGrowth.com and at ir.clouddx.com.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Cloud DX

Accelerating digital healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, 2022 Top Innovator by Canadian Business, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." Cloud DX is an exclusive partner to Medtronic Canada, Teladoc Health Canada, and Equitable Life of Canada.

Cloud DX Investor Site https://ir.clouddx.com/overview/default.aspx

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com

For investor inquiries (Canada):

Jay Bedard
Cloud DX Investor Relations
647-881-8418
investors@CloudDX.com

For investor inquiries (US):

Gary Zwetchkenbaum
Plumtree LLC
Phone 718-224-3123
Cell 516-455-7662
ir@CloudDX.com

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/713957/Cloud-DX-to-Present-on-Teladoc-Partnership-and-More-at-Emerging-Growth-Conference

© 2022 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.